Integrated BioTherapeutics Inc. Awarded $16.3M Contract from the National Institute of Allergy and Infectious Diseases to Develop a Treatment for Marburg Virus DiseaseAyana Gordon2021-05-18T09:46:28-04:0005.19. 2021|Read More
Gary Nabors, Ph.D. Joins Integrated BioTherapeutics Inc. as Executive Vice President and Chief Development OfficerAyana Gordon2021-04-29T09:38:15-04:0009.14. 2020|Read More
Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines and provides strategic updateAyana Gordon2021-04-29T09:33:22-04:0001.06. 2020|Read More
Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibodyAyana Gordon2021-04-27T10:39:03-04:0003.16. 2021|Read More
IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureusAyana Gordon2021-04-27T10:38:41-04:0003.10. 2021|Read More
Safety and Immunogenicity of a 4-Component Toxoid-Based Staphylococcus aureus Vaccine in Rhesus MacaquesAyana Gordon2021-04-27T10:38:22-04:0002.25. 2021|Read More
IBT Receives Phase I SBIR grant from NIAID for development of neutralizing monoclonal antibodies against Marburg VirusHaimi Shiferaw2020-11-01T17:49:14-05:0007.12. 2019|Read More
IBT Receives Phase II STTR grant from NIAID for development of Novel ISTAb therapeutics for B. anthracisHaimi Shiferaw2020-11-01T17:14:30-05:0007.01. 2019|Read More
IBT Receives Phase I SBIR grant from NIAID for development of monoclonal antibodies against Marburg Virus using a novel discovery platformHaimi Shiferaw2020-11-01T17:14:04-05:0003.01. 2019|Read More
